BIBW2992 Dimaleate

CAS No.	850140-73-7	Cat. No.	BCP08915
Name	BIBW2992 Dimaleate
Synonyms	BIBW 2992MA2; BIBW-2992; BIBW2992; BIBW 2992; Afatinib; Afatinib dimaleate;
Formula	C32H33ClFN5O11	M. Wt	718.08

Description	Afatinib dimaleate is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. Afatinib is approved in much of the world (including the United States, Canada, the United Kingdom and Australia) for the treatment of metastatic non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim. It acts as an angiokinase inhibitor.
Related Products	439081-18-2（Afatinib） 850140-72-6（Afatinib）
Pathways	Angiogenesis/Protein Tyrosine Kinase Jak/Stat Pathway
Targets	EGFR HER2

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.